CSIMarket Company Name, Ticker, Customers, else..
 
Ibio inc   (NYSEAMER: IBIO)
Other Ticker:  
 
 
Price: $3.6800 $0.51 16.088%
Day's High: $3.76 Week Perf: 2.51 %
Day's Low: $ 3.09 30 Day Perf: 48.39 %
Volume (M): 259 52 Wk High: $ 4.98
Volume (M$): $ 953 52 Wk Avg: $2.19
Open: $3.14 52 Wk Low: $1.05



 Market Capitalization (Millions $) 34
 Shares Outstanding (Millions) 9
 Employees 14
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Ibio Inc
Ibio Inc. is a biotechnology company based in the United States. It primarily focuses on the development and commercialization of plant-based therapies and vaccines. Ibio utilizes a proprietary technology platform called FastPharming, which enables the rapid production of biologics using plants. The company collaborates with various partners to develop and manufacture therapeutic candidates for diseases such as cancer, fibrosis, and infectious diseases. Ibio also offers contract development and manufacturing services to other pharmaceutical and biotechnology companies.


   Company Address: 11750 Sorrento Valley Road San Diego 92121 CA
   Company Phone Number: 446-0027   Stock Exchange / Ticker: NYSEAMER IBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -1.46%    
EPIX   -1.76%    
MLYS        5.77% 
NRIX   -9.09%    
REGN   -8.06%    
• View Complete Report
   



Product Service News

iBio Expands Cardiometabolic and Obesity Research with Innovative Bispecific Antibody Program

Published Thu, Jan 2 2025 12:32 PM UTC

Abstract: iBio Inc. has announced an expansion of its cardiometabolic and obesity program through the development of a novel bispecific antibody targeting Myostatin and Activin A, building upon the success of its existing anti-Myostatin program. This new therapy aims to promote weight loss, prevent muscle loss, and mitigate weight regain while potentially offering less fre...
Contract

iBio Successfully Closes Sale of Texas Manufacturing Facility, Alleviating $13.2M of Secured Debt

Published Mon, Jun 3 2024 11:00 AM UTC

In recent developments, prominent biopharmaceutical company iBio Inc. has closed the sale of its manufacturing facility located in Texas. This transaction has successfully eliminated approximately $13.2 million of secured debt, signaling significant progress towards the company s financial restructuring. This article aims to provide an overview of this important development...
Partnership

Augmenting Obesity and Cardiometabolic Disease Treatment: iBio and AstralBio's Transformative AI Collaboration

Published Wed, Mar 27 2024 11:00 AM UTC

The fight against obesity and cardiometabolic diseases continues to present significant challenges for the healthcare industry. However, a beacon of hope arises as two leading innovators, iBio and AstralBio, join forces in a transformative collaboration. Harnessing the power of Artificial Intelligence (AI) and precision biologics, this groundbreaking partnership aims to rapi...
Financing Agreement

iBio Secures $15 Million Private Placement with Significant Premium, Bolstering Growth Prospects

Published Tue, Mar 26 2024 11:35 PM UTC

iBio Announces Successful $15.0 Million Private Placement with Significant Premium to Last Close
iBio, a leading biologics contract manufacturing organization, has recently announced a successful private placement offering that raised $15.0 million. The purchase price of $2.85 per share represents a premium of over 148% to the last closing price, indicating strong invest...
Shares

iBio Executes 20-to-1 Reverse Stock Split to Propel Share Value and Market Presence

Published Mon, Nov 27 2023 10:20 PM UTC



iBio, Inc. (NYSEA:IBIO), a leading biotech company specialized in the development and manufacturing of biotherapeutics, has recently declared a 20-to-1 reverse stock split of its common stock. The decision, which received approval from the company s Board of Directors, aims to provide a much-needed boost to the firm s share value and improve overall market percepti...






Ibio Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com